The accreditors of this session require that you periodically check in to verify that you are still attentive. Please click the button below to indicate that you are.
Credits: None available.
With the introduction of current and up-and-coming novel cellular therapeutics, Apheresis collection facilities became center stage as the manufacturer of the starting material through the common pathway of the collection procedure. Workloads for collection facilities have been significantly increased, including additional quality requirements such as audits & accommodating large number of clinical trials. Collection facilities are now facing challenges to ensure continued compliance in the cellular therapy arena. The speakers will share the perspective on this crucial topic and how these challenges can be mitigated. Different efforts in the field to standardize approaches will be shared with the audience as well as dealing with challenging collection scenarios such as patients with complex cardiac history. Attendees will benefit from sharing experiences of the panelists as well as generate ideas and solutions for future success of the field as we move forward with more Cellular Therapy products (commercial & clinical trials). Understanding the challenges around these collections, including management of complex patients’ population, will benefit the field as we bring the product from bench to bedside.
You must be logged in and own this session in order to post comments.